The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIV.g

Vocal cord paresis/paralysis

Publications

Hamada S, Okamoto N, Tsukino M

Bilateral Vocal Cord Paralysis: Pembrolizumab-Induced Delayed-Onset Toxicity in a Patient with Lung Adenocarcinoma.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 Dec;13;e257-e259 — 2018 Dec — e257-e259

Diamantopoulos PT, Tsatsou K, Benopoulou O, Anastasopoulou A, Gogas H

Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.

Journal of immunotherapy (Hagerstown, Md. : 1997) 2017 Jul/Aug;40;221-223 — 2017 Jul/Aug — 221-223